The scale of the problem the guidelines address is stark. Approximately 15 to 25 percent of colorectal cancer patients already have liver metastases when their cancer is first diagnosed, and a further 15 to 25 percent develop such metastases after curative resection of the primary tumor. Critically, 80 to 90 percent of these liver metastases are initially unresectable with curative intent. Left untreated, patients with colorectal liver metastases have a median survival of only 6.9 months, and the five-year survival rate for unresectable disease falls below 5 percent. By contrast, patients who achieve complete resection of their liver metastases, or reach a status of no evidence of disease, experience median survival of 35 to 60 months and five-year overall survival rates of 40 to 57 percent. This dramatic gap between the untreated and the successfully treated is precisely what the new guidelines are designed to close.

On the diagnostic front, the 2025 edition codifies a tiered imaging strategy. For every newly diagnosed colorectal cancer patient, liver ultrasound and contrast-enhanced abdominal computed tomography are recommended as routine screening tools, alongside serum tumor markers such as carcinoembryonic antigen and CA19-9. When ultrasound or CT findings are suspicious but inconclusive, the guidelines endorse supplemental testing with serum alpha-fetoprotein, contrast-enhanced liver ultrasound, and contrast-enhanced liver MRI. Liver-specific contrast-enhanced MRI earns a particularly strong endorsement because it demonstrates higher accuracy for detecting lesions smaller than one centimeter, a critical threshold since tiny metastases are the ones most easily missed and most consequential for surgical planning. PET-CT and PET-MRI are explicitly not recommended for routine use, reserved instead for selected clinical scenarios where additional information is genuinely needed.

The guidelines also formalize a rigorous surveillance program after radical resection of the primary colorectal tumor. Patients should undergo history-taking, physical examination, liver ultrasound and tumor marker testing every three to six months for the first two years, then every six months until five years, and annually thereafter. For patients with stage II and III disease, annual contrast-enhanced CT of the chest, abdomen and pelvis is recommended for three to five years. Electronic colonoscopy should be performed within one year of surgery, with repeat examination at three years and then every five years if no abnormalities are found. After patients achieve no evidence of disease status for liver metastases, the surveillance intensifies further, with tumor markers checked every three months for two years and abdominal imaging every three months during the same period, reflecting the high risk of recurrence in this population.

Perhaps the most consequential section of the 2025 update concerns molecular profiling. The guidelines recommend mismatch repair and microsatellite instability testing for all colorectal cancer patients, a recommendation grounded in the transformative role of immune checkpoint inhibitors in tumors with deficient mismatch repair or high microsatellite instability. RAS genotyping, covering exons 2, 3 and 4 of both KRAS and NRAS, is recommended for all patients with colorectal liver metastases, both for its prognostic value and its role in predicting response to anti-EGFR therapy. BRAF V600E mutation testing is endorsed as both a prognostic indicator and a guide to treatment selection, while HER2 testing is recommended for metastatic patients to inform post-progression decisions. The guidelines also acknowledge emerging biomarkers including tumor mutational burden, POLE and POLD1 mutations, NTRK fusions, RET rearrangements and c-MET alterations, and highlight circulating tumor DNA-based minimal residual disease assessment as a promising but not yet fully validated tool.

On prevention, the guidelines are unequivocal that standardized radical treatment of the primary colorectal cancer remains the most effective strategy for reducing liver metastasis risk. For colon cancer, this means complete mesocolic excision with adequate proximal and distal margins and removal of the associated mesentery and lymphatic drainage. For rectal cancer, total mesorectal excision is mandatory for mid and lower tumors. The update also embraces neoadjuvant approaches aimed at eradicating micrometastases invisible to imaging. For patients with deficient mismatch repair or microsatellite instability-high rectal cancer, immune checkpoint inhibitors can achieve such favorable outcomes that many patients may avoid surgery altogether through a watch-and-wait approach. For proficient mismatch repair tumors staged T3 or higher, or with positive lymph nodes, neoadjuvant radiotherapy, chemoradiotherapy or chemotherapy is recommended, and total neoadjuvant treatment is endorsed as an option that increases complete response rates and facilitates organ preservation.

The multidisciplinary team model receives a Grade A recommendation for all patients with colorectal liver metastases. The guidelines specify that the team should include colorectal or gastrointestinal surgeons, hepatobiliary surgeons, medical oncologists, radiation oncologists, interventional radiologists, diagnostic radiologists, ultrasound specialists and pathologists. The documented advantages of this approach include more accurate molecular profiling, more precise staging, fewer treatment delays, more individualized treatment planning, improved coordination, enhanced quality of life, better survival outcomes and superior cost-effectiveness. The MDT framework is then used to stratify patients into distinct therapeutic pathways: those with initially resectable metastases, those with potentially convertible disease, and those whose metastases will never be resectable, each with tailored goals ranging from cure to disease control.

Surgical treatment remains the gold standard for cure, and the 2025 edition reflects how far the boundaries of resectability have expanded. Surgical decisions are no longer restricted by tumor size, number or location alone. The guidelines now support resection with margins smaller than one centimeter, resection of hepatic pedicle lymph node metastases, and resection of resectable extrahepatic disease including pulmonary and peritoneal metastases. For patients with insufficient future liver remnant volume, the guidelines describe a sophisticated arsenal of techniques: portal vein embolization to induce compensatory hypertrophy, the ALPPS procedure for rapid remnant growth, liver venous deprivation as a less invasive alternative, and selective internal radiation therapy with yttrium-90 microspheres, which can shrink tumors while simultaneously stimulating growth of the untouched liver lobe. Liver transplantation combined with systemic therapy is cautiously endorsed for selected patients with liver-limited disease that cannot achieve no evidence of disease status despite multimodal treatment, an approach supported by the recent TransMet randomized trial showing significantly improved overall survival.

For unresectable disease, the guidelines detail an escalating therapeutic ladder. First-line chemotherapy combines fluoropyrimidines with oxaliplatin and/or irinotecan, with molecular targeted agents such as bevacizumab or cetuximab added to increase conversion to resectability. Triplet FOLFOXIRI regimens are endorsed for fit patients when targeted therapy is contraindicated. For tumors with deficient mismatch repair, immune checkpoint inhibitors such as pembrolizumab or the nivolumab-ipilimumab combination are the preferred first-line approach, having demonstrated significantly improved disease control and conversion rates compared with chemotherapy. Maintenance therapy with low-toxicity regimens after induction, sequential switching between FOLFOX and FOLFIRI upon progression, and later-line options including trifluridine/tipiracil, regorafenib and fruquintinib are all codified. Local therapies including radiofrequency ablation for lesions under three centimeters, microwave ablation for lesions under five centimeters, and stereotactic body radiotherapy for oligometastatic disease round out the comprehensive toolkit, ensuring that even patients whose metastases can never be removed can still expect meaningful prolongation of survival and quality of life.

Subject of Research: Clinical guidelines for the diagnosis and comprehensive treatment of colorectal cancer liver metastases

Article Title: Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastasis (2025 Edition)

Article References: Fan, J., Gu, J., Jia, B., Li, J., Qin, X., Wang, X., Xu, J., Xu, R., Ye, Y., Zhang, S., Zhang, Z., & Chinese College of Surgeons, Chinese Medical Doctor Association (CMDA); Gastrointestinal Surgery Group, Chinese Society of Surgery, Chinese Medical Association (CMA); Colorectal Surgery Group, Chinese Society of Surgery, CMA; Colorectal Cancer Professional Committee, Chinese Anti-Cancer Association; Colorectal Cancer Professional Committee, CMDA; Colorectal Cancer Expert Committee, Chinese Society of Clinical Oncology; Colorectal Surgeon Committee, Chinese College of Surgeons, CMDA; Metastasis Research Com (2026). Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastasis (2025 Edition). Clinical Cancer Bulletin, 5(1), Article 10. https://doi.org/10.1007/s44272-026-00062-6

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00062-6

Keywords: colorectal cancer, liver metastases, clinical guidelines, immunotherapy, hepatic surgery, molecular profiling, chemotherapy, multidisciplinary team, precision medicine, radiofrequency ablation, liver transplantation, biomarkers